摘要
目的探究乌司他丁联合维生素D对重症哮喘合并呼吸衰竭患者的影响。方法选取120例重症哮喘合并呼吸衰竭患者作为研究对象,随机分为对照组和观察组,每组60例。对照组予以常规治疗,观察组在对照组治疗的基础上予以乌司他丁联合维生素D治疗。比较2组的预后恢复情况、血清炎症因子[高敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)、白细胞介素-8(interleukin-8,IL-8)、白细胞介素-17(interleukin-17,IL-17)]、氧化应激反应[超氧化物歧化酶(superoxide dismutase,SOD)、丙二醛(malondialdehyde,MDA)]、肺功能[第1秒用力呼气容积占预计值的百分比(percentage of forced expiratory volume in first second to the expected value,FEV_(1)%)、第1秒用力呼气容积占用力肺活量的比值(the ratio of forced expiratory volume in first second to forced vital capacity,FEV_(1)/FVC)、最大呼气峰流速(peak expiratory flow,PEF)]及不良反应的发生情况。结果治疗后,相较于对照组,观察组咳嗽持续时间、气促持续时间及住院时间均明显缩短(P<0.05);血清hs-CRP、IL-8和IL-17水平均明显降低(P<0.05);血清SOD水平明显升高,MDA水平明显降低(P<0.05);FEV_(1)%、FEV_(1)/FVC、PEF均明显升高(P<0.05);观察组的不良反应总发生率明显低于对照组(P<0.05)。结论乌司他丁联合维生素D可缓解患者的临床症状,缩短住院时间,下调血清炎症因子水平,抑制氧化应激反应,改善肺功能。
Objective To explore the influence of ulinastatin combined with vitamin D in patients with severe asthma complicated with respiratory failure.Methods 120 patients with severe asthma and respiratory failure were selected and randomized into a control group and an observation group,with 60 cases in each group.The control group was given routine treatment,whereas the observation group received ulinastatin combined with vitamin D on the basis of the control group.The prognosis recovery,serum inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),interleukin-8(IL-8),interleukin-17(IL-17)],oxidative stress response[superoxide dismutase(SOD),and malondialdehyde(MDA)],lung function[percentage of forced expiratory volume in first second to the expected value(FEV_(1)%),the ratio of forced expiratory volume in first second to forced vital capacity(FEV_(1)/FVC),and peak expiratory flow(PEF)]and the occurrence of adverse reactions were compared between the 2 groups.Results After treatment,compared with the control group,the duration of cough,duration of shortness of breath and hospitalization time in the observation group were significantly shortened(P<0.05),the levels of serum hs-CRP,IL-8 and IL-17 were significantly reduced(P<0.05),the level of serum SOD was significantly enhanced while the level of MDA was significantly declined(P<0.05),and the FEV_(1)%,FEV_(1)/FVC and PEF were significantly increased(P<0.05),the total incidence of adverse reactions was significantly lower in the observation group(P<0.05).Conclusion Ulinastatin combined with vitamin D can relieve clinical symptoms,shorten hospitalization time,down-regulate serum inflammatory factors,inhibit oxidative stress response and improve lung function.
作者
毛光宇
夏新锋
方玲
骆黎
金澄清
梁清康
MAO Guangyu;XIA Xinfeng;FANG Ling;LUO Li;JIN Chengqing;LIANG Qingkang(Department of Emergency and Intensive Care Medicine,Xiangyang Central Hospital,Affiliated Hospital of Hubei University ofArts and Sciences,Xiangyang 441000,China;Department of Emergency and Intensive Care Medicine,Zhongshan Hospital,Wuhan University,Wuhan 430000,China)
出处
《西北药学杂志》
CAS
2024年第6期69-73,共5页
Northwest Pharmaceutical Journal
基金
湖北省自然科学基金项目(编号:2019CFB203)。
